Health Care [ 3/12 ] | Biotechnology [ 9/75 ]
NASDAQ | Common Stock
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial.
The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025.
ImageneBio, Inc. is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 26 | -0.62 Decreased by -208.90% | - |
| Nov 12, 25 | -2.91 Decreased by -1.29 K% | -1.00 Decreased by -191.00% |
| Jul 24, 25 | -0.69 Decreased by -146.43% | -0.14 Decreased by -386.94% |
| May 8, 25 | -0.17 Increased by +48.48% | -0.19 Increased by +11.41% |
| Mar 6, 25 | -0.20 Increased by +51.22% | -0.21 Increased by +3.24% |
| Nov 7, 24 | -0.21 Increased by +47.50% | -0.25 Increased by +17.61% |
| Aug 9, 24 | -0.28 Increased by +36.36% | -0.36 Increased by +22.22% |
| May 13, 24 | -0.33 Increased by +15.38% | -0.33 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | N/A Decreased by N/A% | -16.16 M Decreased by -77.07% | - - |
| Sep 30, 25 | 0.00 Decreased by -100.00% | -24.78 M Decreased by -142.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | N/A Decreased by N/A% | -2.77 M Increased by +79.85% | - - |
| Mar 31, 25 | N/A Decreased by N/A% | -8.62 M Increased by +46.62% | - - |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -9.12 M Increased by +53.18% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 3.50 M Increased by +195.36% | -10.23 M Increased by +40.99% | Decreased by -292.40% Increased by +80.02% |
| Jun 30, 24 | N/A Decreased by -100.00% | -13.73 M Increased by +19.78% | - - |
| Mar 31, 24 | N/A Decreased by -100.00% | -16.15 M Decreased by -13.55% | - - |